Anita Mercado
Family Medicine · Alhambra, CANPI 1912089970
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 353 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,216, 2.9 times the $770 reported in 2019. Among family medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 353 payments — averaging $25.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- GSK$876
- Bayer$734
- AstraZeneca$715
- AbbVie$671
- plus $4K from 35 others
Across 40 payments — averaging $2750.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$80K
- Novo Nordisk AS$17K
- AstraZeneca$13K
- Merck$116
What the payments were for
- Travel & lodging$140%
- Food & beverage$8,971100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,998 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 111 | $135,062 |
| JardianceEmpagliflozin | 95 | $94,344 |
| OzempicSemaglutide | 43 | $76,002 |
| EliquisApixaban | 50 | $29,676 |
| KerendiaFinerenone | 30 | $28,635 |
| RybelsusSemaglutide | 19 | $26,097 |
| XareltoRivaroxaban | 24 | $22,029 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $21,462 |
| MounjaroTirzepatide | 19 | $21,363 |
| ProliaDenosumab | 13 | $19,974 |
| TradjentaLinagliptin | 30 | $18,865 |
| JanuviaSitagliptin Phosphate | 23 | $18,179 |
| GemtesaVibegron | 18 | $16,668 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 19 | $13,232 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 33 | $9,326 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $715 | $135,062111 claims |
| Boehringer IngelheimJardiance, Tradjenta | $220 | $113,210125 claims |
| Novo NordiskOzempic, Rybelsus | $1,011 | $102,09862 claims |
| MerckJanuvia, Janumet Xr | $174 | $31,41142 claims |
| GSKTrelegy Ellipta, Arexvy | $876 | $30,78952 claims |
| PfizerEliquis | $77 | $29,67650 claims |
| BayerKerendia | $734 | $28,63530 claims |
| Johnson & JohnsonXarelto | $26 | $22,02924 claims |
| Lilly USA, LLCMounjaro | $1,216 | $21,36319 claims |
| AmgenProlia | $452 | $19,97413 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $164 | $16,66818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Alhambra
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.